Structure Therapeutics
Structure Therapeutics
GPCR
NASDAQ
22.00
USD
2.71%
About
Structure Therapeutics Inc. is a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases. It is focused on G-protein coupled receptors (GPCRs) as a therapeutic target class. Its product candidates include GSBR-1290, Amylin, glucose-dependent insulinotropic polypeptide receptor (GIPR), GCGR, ANPA-0073 and LTSE-2578.
It is developing GSBR-1290, its oral small molecule product candidate targeting the validated glucagon-like-peptide-1 receptor (GLP-1R) for the treatment of type 2 diabetes mellitus (T2DM) and obesity. It is developing GLP-1R candidates, including dual GLP-1R/GIPR agonists and amylin agonists, each designed with customized properties to achieve additional benefit.
It is developing ANPA-0073, an investigational oral small molecule APJR agonist, for the treatment of idiopathic pulmonary fibrosis (IPF). It is evaluating its LPA1R program, LTSE-2578 for IPF and progressive pulmonary fibrosis..
Financials Amount (in millions)
Income statement
Balance sheet
Cash flow
Ratios
| Price and Volume | |
|---|---|
| Volume | |
| Ten Day Average Volume | 525.7K |
| Three Month Average Volume | 25.1M |
| High Low | |
| Fifty-Two Week High | 75.0167 USD |
| Fifty-Two Week Low | 26.61 USD |
| Fifty-Two Week High Date | 01 Nov 2023 |
| Fifty-Two Week Low Date | 18 Dec 2023 |
| Price and Volume | |
| Current Price | 38.13 USD |
| Beta | -100,000 |
| Relative Price Change | |
| Four Week Relative Price Change | 0.59% |
| Thirteen Week Relative Price Change | 4.17% |
| Twenty-Six Week Relative Price Change | -15.91% |
| Fifty-Two Week Relative Price Change | 7.94% |
| Year-to-Date Relative Price Change | -21.00% |
| Price Change | |
| One Day Price Change | -0.50% |
| Thirteen Week Price Change | 11.49% |
| Twenty-Six Week Price Change | -7.54% |
| Five Day Price Change | -4.17% |
| Fifty-Two Week Price Change | 35.26% |
| Year-to-Date Price Change | -6.45% |
| Month-to-Date Price Change | 1.98% |
| Per Share Data | |
|---|---|
| Book Value | |
| Book Value Per Share (Last Fiscal Year) | 9.7608 USD |
| Book Value Per Share (Most Recent Quarter) | 16.10299 USD |
| Tangible Book Value Per Share (Last Fiscal Year) | 9.7608 USD |
| Tangible Book Value Per Share (Most Recent Quarter) | 16.10299 USD |
| EBITD | |
| EBITD Per Share (Trailing Twelve Months) | -2.69886 USD |
| Revenue | |
| Revenue Per Share (Last Fiscal Year) | 0 USD |
| Revenue Per Share (Trailing Twelve Months) | 0 USD |
| Dividend | |
| Dividend Per Share (Last Fiscal Year) | -99999.99 USD |
| Dividend Per Share (Trailing Twelve Months) | 0 USD |
| Dividend Per Share (5 Year) | -99999.99 USD |
| Earnings Per Share | |
| Excluding Extraordinary Items (Last Fiscal Year) | -2.43978 USD |
| Excluding Extraordinary Items (Trailing Twelve Months) | -2.23773 USD |
| Normalized (Last Fiscal Year) | -2.43978 USD |
| Basic Excluding Extraordinary Items (Last Fiscal Year) | -2.43978 USD |
| Basic Excluding Extraordinary Items (Trailing Twelve Months) | -2.23773 USD |
| Including Extraordinary Items (Last Fiscal Year) | -2.43978 USD |
| Including Extraordinary Items (Trailing Twelve Months) | -2.23773 USD |
| Cash | |
| Cash Per Share (Last Fiscal Year) | 10.07017 USD |
| Cash Per Share (Most Recent Quarter) | 16.20941 USD |
| Cash Flow Per Share (Last Fiscal Year) | -2.43176 USD |
| Cash Flow Per Share (Trailing Twelve Months) | -2.21087 USD |
| Free Cash Flow Per Share (Trailing Twelve Months) | -2.33254 USD |
| Margins | |
|---|---|
| Cash Flow Revenue | |
| Cash Flow Revenue (5 Year) | -100,000 |
| Cash Flow Revenue (Trailing Twelve Months) | -100,000 |
| Pretax Margin | |
| Pretax Margin (Trailing Twelve Months) | -99,999.99% |
| Pretax Margin (Last Fiscal Year) | -99,999.99% |
| Pretax Margin (5 Year) | -99,999.99% |
| Gross Margin | |
| Gross Margin (Last Fiscal Year) | -99,999.99% |
| Gross Margin (Trailing Twelve Months) | -99,999.99% |
| Gross Margin (5 Year) | -99,999.99% |
| Operating Margin | |
| Operating Margin (Last Fiscal Year) | -99,999.99% |
| Operating Margin (Trailing Twelve Months) | -99,999.99% |
| Operating Margin (5 Year) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin (Last Fiscal Year) | -99,999.99% |
| Net Profit Margin (Trailing Twelve Months) | -99,999.99% |
| Net Profit Margin (5 Year) | -99,999.99% |
| Growth | |
|---|---|
| Book Value | |
| Book Value Per Share (5 Year) | -99,999.99% |
| Tangible Book Value (5 Year) | -99,999.99% |
| Free Operating Cash Flow | |
| Free Operating Cash Flow (5 Year) | -99,999.99% |
| Revenue | |
| Revenue Change MRQ vs 1 Year Ago | -99,999.99% |
| Revenue Growth (3 Year) | -99,999.99% |
| Revenue Change (Trailing Twelve Months) | -99,999.99% |
| Revenue Per Share Growth | -99,999.99% |
| Revenue Growth (5 Year) | -99,999.99% |
| Capital Spending Debt | |
| Capital Spending (5 Year) | -99,999.99% |
| Total Debt (5 Year) | -99,999.99% |
| Dividends | |
| Dividend Growth (3 Year) | -99,999.99% |
| Earnings Per Share | |
| EPS Change MRQ vs 1 Year Ago | 13.43% |
| EPS Change (Trailing Twelve Months) | -10.50% |
| EPS Growth (3 Year) | -99,999.99% |
| EPS Growth (5 Year) | -99,999.99% |
| EBITDA | |
| EBITDA (5 Year) | -99,999.99% |
| EBITDA (5 Year Interim) | -99,999.99% |
| Net Profit Margin | |
| Net Profit Margin Growth (5 Year) | -99,999.99% |
| Valuation | |
|---|---|
| Total Price to Book | |
| Price to Tangible Book (Last Fiscal Year) | 5 |
| Price to Tangible Book (Most Recent Quarter) | 2 |
| Price to Free Cash Flow | |
| Price to Free Cash Per Share (Last Fiscal Year) | -100,000 |
| Price to Free Cash Per Share (Trailing Twelve Months) | -100,000 |
| Net Debt | |
| Net Debt (Most Recent Quarter) | -927,119,000 |
| Net Debt (Last Fiscal Year) | -467,323,000 |
| Price to Sales | |
| Price to Sales (Last Fiscal Year) | -100,000 |
| Price to Sales (Trailing Twelve Months) | -100,000 |
| Price to Earnings | |
| PE Excluding Extraordinary Items (Last Fiscal Year) | -100,000 |
| PE Normalized (Last Fiscal Year) | -100,000 |
| PE Basic Excluding Extraordinary Items (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items High (Trailing Twelve Months) | -100,000 |
| PE Excluding Extraordinary Items Low (Trailing Twelve Months) | -100,000 |
| PE Including Extraordinary Items (Trailing Twelve Months) | -100,000 |
| Dividends | |
| Dividend Yield (5 Year) | -99,999.99% |
| Dividend Yield | -99,999.99% |
| Current Dividend Yield | 0.00% |
| Price to Book | |
| Price to Book (Last Fiscal Year) | 4 |
| Price to Book (Most Recent Quarter) | 2 |
| Financial Strength | |
|---|---|
| Debt to Equity | |
| Long Term Debt to Equity (Last Fiscal Year) | 0 |
| Long Term Debt to Equity (Most Recent Quarter) | 0 |
| Payout Ratio | |
| Payout Ratio (Last Fiscal Year) | -99,999.99% |
| Payout Ratio (Trailing Twelve Months) | -99,999.99% |
| Quick Ratio | |
| Quick Ratio (Last Fiscal Year) | -100,000 |
| Quick Ratio (Most Recent Quarter) | -100,000 |
| Enterprise Value | |
| Current Enterprise Value to Free Cash Flow (Last Fiscal Year) | -100,000 |
| Current Enterprise Value to Free Cash Flow (Trailing Twelve Months) | -100,000 |
| Current Ratio | |
| Current Ratio (Last Fiscal Year) | 19 |
| Current Ratio (Most Recent Quarter) | 41 |
| Free Cash Flow | |
| Free Cash Flow (Last Fiscal Year) | -81,655,000 |
| Free Cash Flow (Trailing Twelve Months) | -105,324,000 |
| Net Interest Coverage | |
| Net Interest Coverage (Last Fiscal Year) | -100,000 |
| Net Interest Coverage (Trailing Twelve Months) | -100,000 |
| Total Debt to Equity | |
| Total Debt to Equity (Last Fiscal Year) | 0 |
| Total Debt to Equity (Most Recent Quarter) | 0 |
| Management Effectiveness | |
|---|---|
| Return on Assets | |
| Return on Assets (Last Fiscal Year) | -30.91% |
| Return on Assets (Trailing Twelve Months) | -17.07% |
| Return on Assets (5 Year) | -99,999.99% |
| Return on Equity | |
| Return on Equity (Last Fiscal Year) | -53.06% |
| Return on Equity (Trailing Twelve Months) | -17.69% |
| Return on Equity (5 Year) | -99,999.99% |
| Return on Investment | |
| Return on Investment (Last Fiscal Year) | -33.06% |
| Return on Investment (Trailing Twelve Months) | -17.64% |
| Return on Investment (5 Year) | -99,999.99% |